Relief Therapeutics Holding SA (SWX: RLF)

Market Cap	19.50M
Revenue (ttm)	8.60M
Net Income (ttm)	-46.24M
Shares Out	12.54M
EPS (ttm)	-3.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,231
Open	1.550
Previous Close	1.555
Day's Range	1.550 - 1.820
52-Week Range	1.055 - 4.200
Beta	-14.74
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2024

About RLF

Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 49
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: RLF

Financial Performance

In 2023, STRN's revenue was 128.57 million, an increase of 16.41% compared to the previous year's 110.45 million. Earnings were 5.89 million, an increase of 71.74%.